{"prompt": "['LINEBERGER COMPREHENSIVE CANCER CENTER', 'CLINICAL ONCOLOGY RESEARCH PROGRAM', 'April 2017', 'UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL', 'LCCC 1726:', 'Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the', 'Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation', 'Principal Investigator', 'Zev Nakamura, MD', '101 Manning Drive', 'Campus Box 7160', 'Chapel Hill, NC 27599', '984-974-3829 (PHONE)', '984-974-9646 (FAX)', 'Email:zev_nakamura@med.unc.edu', 'Signature Page', 'The signature below constitutes the approval of this protocol and the attachments, and', 'provides the necessary assurances that this trial will be conducted according to all', 'stipulations of the protocol, including all statements regarding confidentiality, and', 'according to local legal and regulatory requirements and applicable U.S. federal regulations', 'and ICH guidelines.', 'Principal Investigator (PI) Name:', 'Zev Nakamura M.D.', 'PI Signature:', 'you nother MD', 'Date:', '3/16/2020', 'Version date: 3/16/2020']['LCCC XXXX', 'CONFIDENTIAL', 'PI: Zev Nakamura', 'UNIVERSITY OF NORTH CAROLINA', 'April 2017', 'TABLE OF CONTENTS', '1.0', 'BACKGROUND AND RATIONALE', '4', '1.1', 'Study Synopsis', '4', '1.2', 'Disease Background', '4', '1.3', 'Current Standard of Care', '6', '1.4', 'High Dose Intravenous Thiamine', '6', '1.5', 'Rationale for Clinical Study', '7', '2.0', 'STUDY OBJECTIVES', '7', '2.1', 'Primary Objectives', '7', '2.2', 'Secondary Objectives', '7', '3.0', 'Criteria for Evaluation / Study Endpoints', '8', '3.1', 'Primary Endpoint', '8', '3.2', 'Secondary Endpoints', '8', '4.0', 'PATIENT ELIGIBILITY', '8', '4.1', 'Inclusion Criteria', '8', '4.2', 'Exclusion Criteria', '8', '5.0', 'TREATMENT PLAN', '9', '5.1', 'Schema', '9', '5.2', 'Treatment Dosage and Administration', '9', '5.3', 'Toxicities and Dosing Delays', '10', '5.4', 'Usual Care', '10', '5.5', 'Prohibited Medications/Treatments', '11', '5.6', 'Duration of Therapy', '11', 'i']['LCCC XXXX', 'CONFIDENTIAL', 'PI: Zev Nakamura', 'UNIVERSITY OF NORTH CAROLINA', 'April 2017', '5.7', 'Duration of Follow Up', '11', '5.8', 'Study Withdrawal', '11', '5.9', 'Study Questionnaires', '12', '6.0', 'DRUG INFORMATION', '13', '6.1', 'Thiamine Description and Management', '13', '7.0', 'EVALUATIONS AND ASSESSMENTS', '14', '7.1', 'Time and Events Table', '14', '7.3', 'Randomization', '15', '7.4', 'Post-Transplant Days 1 - 30 Assessments', '15', '7.5', 'Long-term Follow-Up Assessments', '16', '7.6', 'Concurrent CNS Active Medications', '16', '7.7', 'Demographics', '16', '7.8', 'Delirium Risk Factors', '16', '7.9', 'Handling of Biospecimens Collected for Correlative Research', '16', '7.10', 'Assessment of Safety', '17', '7.11', 'Assessment of Efficacy', '17', '8.0', 'ADVERSE EVENTS', '18', '8.1', 'Definitions', '18', '8.2', 'Documentation of non-serious AEs or SARs', '19', '8.3', 'SAEs or Serious SARs', '20', '8.4', 'Adverse Event Reporting', '20', '8.5', 'Data and Safety Monitoring Plan', '20', '9.0', 'STATISTICAL CONSIDERATIONS', '21', '9.1', 'Study Design/Study Endpoints', '21', 'ii']\n\n###\n\n", "completion": "END"}